Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Klocker

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
The Journal of Urology|June 19, 2007
Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate developmentA Lunacek, C Schwentner, J Oswald, et al.
British Journal of Cancer|October 29, 1998
Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cellsZ Culig, A Hobisch, M Herold, et al.
The Prostate|March 1, 1996
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsM V Cronauer, H Klocker, H Talasz, et al.
The Prostate|June 1, 1997
Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostateM V Cronauer, A Hittmair, I E Eder, et al.
Prostate Cancer and Prostatic Diseases|February 6, 2013
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancerG Schaefer, J-M Mosquera, R Ramoner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of ScreeningN Mühlberger, E A M Heijnsdijk, C Kurzthaler, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2017
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter studyI Heidegger, H Klocker, R Pichler, et al.
The Journal of Urology|March 29, 2000
Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostateR Ischia, A Hobisch, R Bauer, et al.
Oncogene|August 11, 2015
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancerM Puhr, J Hoefer, A Eigentler, et al.
Molecular and Cellular Biology|April 5, 2001
Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5W Doppler, M Windegger, C Soratroi, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
The Journal of Urology|June 19, 2007
Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate developmentA Lunacek, C Schwentner, J Oswald, et al.
British Journal of Cancer|October 29, 1998
Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cellsZ Culig, A Hobisch, M Herold, et al.
The Prostate|March 1, 1996
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsM V Cronauer, H Klocker, H Talasz, et al.
The Prostate|June 1, 1997
Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostateM V Cronauer, A Hittmair, I E Eder, et al.
Prostate Cancer and Prostatic Diseases|February 6, 2013
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancerG Schaefer, J-M Mosquera, R Ramoner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of ScreeningN Mühlberger, E A M Heijnsdijk, C Kurzthaler, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2017
ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter studyI Heidegger, H Klocker, R Pichler, et al.
The Journal of Urology|March 29, 2000
Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostateR Ischia, A Hobisch, R Bauer, et al.
Oncogene|August 11, 2015
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancerM Puhr, J Hoefer, A Eigentler, et al.
Molecular and Cellular Biology|April 5, 2001
Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5W Doppler, M Windegger, C Soratroi, et al.
Pageof 15